IRIS PubliCatt

Ciccullo, Arturo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 874
EU - Europa 551
AS - Asia 309
AF - Africa 8
OC - Oceania 4
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 865
SE - Svezia 205
CN - Cina 123
IT - Italia 105
SG - Singapore 72
FR - Francia 69
DE - Germania 66
IN - India 59
IE - Irlanda 44
ID - Indonesia 28
RU - Federazione Russa 15
BE - Belgio 10
CA - Canada 9
GB - Regno Unito 9
FI - Finlandia 7
KR - Corea 6
UA - Ucraina 6
TR - Turchia 4
CH - Svizzera 3
ES - Italia 3
IR - Iran 3
JP - Giappone 3
PL - Polonia 3
TW - Taiwan 3
AU - Australia 2
CI - Costa d'Avorio 2
CL - Cile 2
EU - Europa 2
NL - Olanda 2
NZ - Nuova Zelanda 2
TZ - Tanzania 2
YE - Yemen 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
CM - Camerun 1
EG - Egitto 1
HK - Hong Kong 1
KZ - Kazakistan 1
LT - Lituania 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
PT - Portogallo 1
RO - Romania 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZA - Sudafrica 1
ZW - Zimbabwe 1
Totale 1.751
Salva come PNG Salva come JPEG
Città #
Chandler 314
Ashburn 67
New York 62
Singapore 55
Dublin 44
San Mateo 36
Beijing 34
Jakarta 28
Princeton 28
Boston 27
Wilmington 27
Rome 24
Nanjing 21
Dearborn 17
Marseille 17
Redwood City 16
Cattolica 14
Milan 11
Brussels 10
Moscow 10
Fairfield 8
Pune 8
Changsha 7
Chicago 7
Guangzhou 6
Helsinki 6
Los Angeles 6
Hangzhou 5
Jacksonville 5
Jinan 5
Nanchang 5
Seattle 5
Busto Arsizio 4
Hefei 4
Jiaxing 4
Munich 4
Ottawa 4
Shenyang 4
Ann Arbor 3
Augusta 3
Frankfurt am Main 3
Kunming 3
Leawood 3
London 3
Mumbai 3
Paris 3
Tianjin 3
Toronto 3
Zurich 3
Abidjan 2
Alcalá de Henares 2
Ardabil 2
Busan 2
Cambridge 2
Chengdu 2
Dar es Salaam 2
Falkenstein 2
Fuzhou 2
Genoa 2
Hebei 2
Hyderabad 2
Kraków 2
Mountain View 2
Redmond 2
Rizziconi 2
San Francisco 2
Sanaa 2
Santa Clara 2
Seoul 2
Tokyo 2
Trezzo sull'Adda 2
Vancouver 2
Woodbridge 2
Almaty 1
Amsterdam 1
Andover 1
Auckland 1
Baltimore 1
Bangalore 1
Bucharest 1
Buffalo 1
Cairo 1
Central District 1
Changchun 1
Clearwater 1
Cleveland 1
Dong Ket 1
Durban 1
Edinburgh 1
Esslingen am Neckar 1
Fabriano 1
Falls Church 1
Florence 1
Guangdong 1
Gunzenhausen 1
Harare 1
Houston 1
Izmir 1
Lawrence 1
Lisbon 1
Totale 1.067
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 105
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 91
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 85
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 76
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 75
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 73
Shall we dance? Extending tango's results to clinical practice 73
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 70
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 69
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 68
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 65
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 65
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 60
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 59
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 58
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 58
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 57
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 57
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 56
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 54
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 53
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 51
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 50
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 49
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 49
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 49
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 48
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 45
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 43
Totale 1.811
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.104
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020178 0 0 0 0 4 21 16 4 19 14 94 6
2020/2021103 6 1 4 2 8 4 4 2 6 26 31 9
2021/2022282 29 2 7 46 9 5 5 42 6 22 37 72
2022/2023684 102 96 63 106 39 71 33 57 78 2 25 12
2023/2024308 14 78 6 35 6 93 15 1 4 11 17 28
2024/2025139 13 11 41 30 44 0 0 0 0 0 0 0
Totale 1.811